Syncromune, Inc.

NXP800 Shows Promise in Overcoming Hormone Resistance in Advanced Prostate Cancer

4 months ago

• NXP800, an innovative drug, demonstrates potential in treating advanced prostate cancer resistant to hormone therapies like enzalutamide. • The drug targets the heat shock factor 1 (HSF1) pathway, crucial for cancer cell survival under stress, offering a novel approach to treatment. • Research indicates that higher levels of heat shock proteins are associated with poorer outcomes in prostate cancer patients, highlighting NXP800's relevance. • Preclinical studies show NXP800 slows prostate cancer growth, even in hormone therapy-resistant models, warranting further clinical trials.

SYNC-T SV-102 Shows Promising Response in Metastatic Castration-Resistant Prostate Cancer

6 months ago

• SYNC-T SV-102, a multi-target immunotherapy, demonstrated an 85% objective response rate in patients with metastatic castration-resistant prostate cancer (CRPC). • The LEGION-100 trial combines cryoablation with intra-tumoral immunotherapy to stimulate the immune system against solid tumors. • The FDA cleared the IND application for SYNC-T SV-102 in May 2024, marking a significant step in its clinical development for CRPC. • Early data indicates SYNC-T SV-102 is well-tolerated, with complete resolution of bone metastases observed in a notable percentage of patients.